Interferon-β1a and Endothelial Microparticles in Multiple Sclerosis
Author Information
Author(s): William A Sheremata, Wenche Jy, Sylvia Delgado, Alireza Minagar, Jerry McLarty, Yeon Ahn
Primary Institution: University of Miami
Hypothesis
The treatment with interferon-β1a will reduce plasma levels of CD31+ endothelial microparticles in patients with multiple sclerosis.
Conclusion
Interferon-β1a treatment significantly reduces plasma levels of CD31+EMP, suggesting it may serve as a surrogate marker of response to therapy in multiple sclerosis.
Supporting Evidence
- Plasma levels of CD31+EMP were significantly reduced from 24 through 52 weeks following initiation of treatment.
- At study entry, only one of the pretreatment CD31+EMP values in MS patients was within normal range.
- The decrease in plasma CD31+EMP levels reflects a reduction in CD4+ cell interaction with the endothelium.
Takeaway
This study found that a medicine called interferon-β1a helps lower certain tiny particles in the blood of people with multiple sclerosis, which might show how well the treatment is working.
Methodology
Plasma CD31+EMP levels were measured in 30 patients with relapsing-remitting MS before and after treatment with interferon-β1a at multiple time points using flow cytometry.
Potential Biases
Potential bias due to the lack of blinding in the treatment assignment.
Limitations
The study had a small sample size and lacked a control group for the treatment.
Participant Demographics
Mean age of participants was 41.1 years, predominantly female.
Statistical Information
P-Value
0.016
Confidence Interval
95% confidence limits of the mean
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website